HPV16 L1 Antibody (289-16981): sc-57834

HPV16 L1 Antibody (289-16981) is a mouse monoclonal IgG2a antibody that detects HPV16 L1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. HPV16 L1 plays a crucial role in the life cycle of human papillomavirus type 16, which is known to infect the genital tract and is associated with cervical cancer. HPV16 L1 is primarily located in the upper layers of the infected epithelium, where expression occurs, and forms the pentameric assembly unit of the viral capsid. This structural arrangement is vital for the virus′s ability to package its genome and facilitate infection. The C-terminus of HPV16 L1 is essential for both binding to DNA and the subsequent packaging of the viral genome, underscoring its importance in the viral life cycle. HPV16 L1 can package unrelated plasmid DNA in vitro, demonstrating potential as a tool for gene delivery into eukaryotic cells. The unique localization of HPV16 L1, which shows a diffuse nuclear distribution, contrasts with the punctate nuclear regions occupied by the minor capsid protein L2, highlighting the distinct roles these proteins play in the viral assembly process. Anti-HPV16 L1 antibody (289-16981) is an invaluable tool for researchers studying the mechanisms of HPV infection and the development of cervical cancer.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HPV16 L1 Antibody (289-16981) References:

1. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles.  |  Zhou, J., et al. 1992. Virology. 189: 592-9. PMID: 1379392
2. Correlation of HPV16 L1 capsid protein expression in cervical dysplasia with HPV16 DNA concentration, HPV16 E6*I mRNA and histologic outcome.  |  Kösel, S., et al. 2009. Acta Cytol. 53: 396-401. PMID: 19697723
3. HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions.  |  Mehlhorn, G., et al. 2014. Anticancer Res. 34: 5127-32. PMID: 25202103
4. HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer.  |  Namvar, A., et al. 2016. Bratisl Lek Listy. 117: 179-84. PMID: 26925750
5. Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females.  |  Yokomine, M., et al. 2017. Exp Ther Med. 13: 1500-1505. PMID: 28413500
6. hnRNP G prevents inclusion on the HPV16 L1 mRNAs of the central exon between splice sites SA3358 and SD3632.  |  Yu, H., et al. 2018. J Gen Virol. 99: 328-343. PMID: 29458523
7. Brucella abortus RB51 lipopolysaccharide influence as an adjuvant on the therapeutic efficacy of HPV16 L1 and HPV16 E7 DNA vaccines.  |  Shirmohammadi, M., et al. 2021. Iran J Basic Med Sci. 24: 92-97. PMID: 33643576
8. Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy.  |  Chen, J., et al. 2021. Sci Rep. 11: 20083. PMID: 34635698
9. A bioinformatics approach for identifying the probable cause of the cross-interaction of antibodies to the antigenic protein HPV16 L1 with the HPV6 L1 protein.  |  Stolbikov, AS., et al. 2021. Vavilovskii Zhurnal Genet Selektsii. 25: 787-792. PMID: 34950850
10. High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study.  |  Prétet, JL., et al. 2023. Clin Exp Med. 23: 87-96. PMID: 35199231

The preferred HPV16 L1 antibody is HPV16 L1 Antibody (CAMVIR-1): sc-47699.